DuChemBIO Co.,Ltd. (176750.KQ)
KOSDAQ · KRW · Healthcare · Drug Manufacturers - Specialty & Generic
₩6,920 (-1.98%) as of
Key statistics
- Market cap
- 196.38B
- Dividend yield
- 0.00%
- 52-week range
- 5,100.00 – 12,770.00
- Beta
- -0.03
- Revenue (TTM)
- 41.51B
- Profit margin
- 16.45%
- Volume
- 216.03k
About DuChemBIO Co.,Ltd.
DuChemBIO Co.,Ltd. engages in the development, production, and sale of radiopharmaceutical products for cancer diagnosis and treatment in South Korea. Its products include FP-CIT for diagnosis of Parkinson's disease and Parkinson's syndrome by measuring the density of dopamine transporters present in the brain striatum; F-DOPA for brain tumor diagnosis with neutralization technology; Neuraceq for diagnosis of Alzheimer's disease by measuring the distribution and density of beta amyloid in the brain; and Vizamyl for early diagnosis of beta amyloid in Alzheimer's disease. The company also offers FES, a solution for diagnosis of metastatic breast cancer and determination of estrogen receptor status; FACBC for prostate cancer diagnosis; FDG for the diagnosis of tumors; and NaF for the diagnosis of bone-related diseases. DuChemBIO Co.,Ltd. was founded in 2002 and is based in Seoul, South Korea.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Seoul, South Korea
- Employees
- 146
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.